Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 111
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 108
The amyloid cascade hypothesis: an updated critical review
Kasper P. Kepp, Nikolaos K. Robakis, Poul Flemming Høilund‐Carlsen, et al.
Brain (2023) Vol. 146, Iss. 10, pp. 3969-3990
Open Access | Times Cited: 105
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Martin T. Henrich, Wolfgang H. Oertel, D. James Surmeier, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 82
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Jimena Tatiana Hathaway, Madhura Shah, David Hathaway, et al.
JAMA Ophthalmology (2024) Vol. 142, Iss. 8, pp. 732-732
Closed Access | Times Cited: 66
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 47-55
Closed Access | Times Cited: 58
Understanding the Gut–Brain Axis and Its Therapeutic Implications for Neurodegenerative Disorders
Yadong Zheng, Laura Bonfili, Tao Wei, et al.
Nutrients (2023) Vol. 15, Iss. 21, pp. 4631-4631
Open Access | Times Cited: 45
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 45
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 17
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cindy X. Cai, Michelle R. Hribar, Sally L. Baxter, et al.
JAMA Ophthalmology (2025)
Closed Access | Times Cited: 3
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Leszek Szablewski
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 542-542
Open Access | Times Cited: 1
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
Zhaojun Wang, Xinru Li, Shi-Fan Chai, et al.
Neuropharmacology (2023) Vol. 240, pp. 109716-109716
Closed Access | Times Cited: 39
A Triterpenoid Lupeol as an Antioxidant and Anti-Neuroinflammatory Agent: Impacts on Oxidative Stress in Alzheimer’s Disease
Jun Sung Park, Inayat Ur Rehman, Kyonghwan Choe, et al.
Nutrients (2023) Vol. 15, Iss. 13, pp. 3059-3059
Open Access | Times Cited: 30
Physical activity and lifestyle modifications in the treatment of neurodegenerative diseases
José A. Santiago, Judith A. Potashkin
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 28
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases
Elizabeth M. Rhea, Alice Babin, P. C. Thomas, et al.
Tissue Barriers (2023) Vol. 12, Iss. 4
Open Access | Times Cited: 24
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease
Niklas Reich, Christian Hölscher
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101122-101122
Open Access | Times Cited: 14
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Guy Pelletier, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 617-617
Open Access | Times Cited: 11
Liraglutide Reduces Alcohol Consumption, Anxiety, Memory Impairment, and Synapse Loss in Alcohol Dependent Mice
Weizhen Liu, Ziliang Wang, Wang Wang, et al.
Neurochemical Research (2024) Vol. 49, Iss. 4, pp. 1061-1075
Open Access | Times Cited: 9
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 8
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 16
The regulating effect of curcumin on NF-κB pathway in neurodegenerative diseases: a review of the underlying mechanisms
Niusha Esmaealzadeh, Mahdis Sadat Miri, Helia Mavaddat, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 4, pp. 2125-2151
Closed Access | Times Cited: 7
Comparative Effects of GLP-1 Receptor Agonists and Metformin on Glaucoma Risk in Type 2 Diabetes Patients
Jawad Muayad, Asad Loya, Zain Hussain, et al.
Ophthalmology (2024)
Closed Access | Times Cited: 7
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jiang, Ji Li, Xiaohui Yao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
Alessandra Dei, M. M. Micheli, Raffaella Aldigeri, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 9, pp. 2339-2349
Open Access | Times Cited: 6
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Lidan Hu, Wenmin Wang, Xiangjun Chen, et al.
Brain‐X (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top